Shares of our first idea today jumped overnight on news that the company received good results on a drug for central nervous system disorders. You might want to watch for a bit of a pullback before buying. Our other recommendations are selling previous ideas, with some profit-taking.
Alexion Pharmaceuticals, Inc. (ALXN)
From Cabot Undervalued Stocks Advisor
Alexion Pharmaceuticals, Inc. (ALXN) is a biopharmaceutical company that researches and manufactures treatments of severe and rare health disorders. Investors may listen to the webcast of Alexion’s September 14 presentation at Morgan Stanley’s 16th Annual Global Healthcare Conference. ALXN is an undervalued aggressive growth stock. Analysts expect EPS to grow 23.4% and 19.1%. The corresponding P/Es are 16.2 and 13.6. The stock recently pulled back near four-month price support at 115, and is slowly rebounding. There’s 24% upside to 147 where ALXN last traded in September 2017. Buy ALXN now. Strong Buy.
Crista Huff, Cabot Undervalued Stocks Advisor, www.cabotwealth.com, 978-745-5532, September 18, 2018